Literature DB >> 16838181

Regulatory T cells in graft-versus-host disease.

Benoît L Salomon1, Muriel Sudres, José L Cohen.   

Abstract

Alloreactive T cells present in a bone marrow transplant are responsible for graft-vs-host disease, but their depletion is associated with impaired engraftment, immunosuppression, and loss of the graft-vs-leukemia effect. The subpopulation of CD4(+)CD25(+) immunoregulatory T cells was first identified based on its crucial role in the control of autoimmune processes, but they also play a role in alloreactive responses. Moreover, these cells could be used to develop innovative strategies in the field of transplantation and particularly to prevent graft-vs-host disease. Indeed, high numbers of CD4(+)CD25(+) immunoregulatory T cells can modulate graft-vs-host disease if administered at the same time as allogeneic hematopoietic stem cell transplantation in mice. This review discusses various important issues regarding the possible use of CD4(+)CD25(+) immunoregulatory T cells to modulate alloreactivity in hematopoietic stem cell transplantation.

Entities:  

Mesh:

Year:  2006        PMID: 16838181     DOI: 10.1007/s00281-006-0020-9

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  51 in total

1.  Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.

Authors:  A M Thornton; E M Shevach
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.

Authors:  M Hara; C I Kingsley; M Niimi; S Read; S E Turvey; A R Bushell; P J Morris; F Powrie; K J Wood
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

3.  Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.

Authors:  Aurélie Trenado; Muriel Sudres; Qizhi Tang; Sébastien Maury; Frédéric Charlotte; Sylvie Grégoire; Mark Bonyhadi; David Klatzmann; Benoît L Salomon; José L Cohen
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 4.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

Review 5.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

6.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

7.  Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.

Authors:  Guliang Xia; Mike Kovochich; Robert L Truitt; Bryon D Johnson
Journal:  Biol Blood Marrow Transplant       Date:  2004-11       Impact factor: 5.742

8.  Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ.

Authors:  Britt E Anderson; Jennifer M McNiff; Dhanpat Jain; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2004-11-02       Impact factor: 22.113

9.  Donor APCs are required for maximal GVHD but not for GVL.

Authors:  Catherine C Matte; Jinli Liu; James Cormier; Britt E Anderson; Ioanna Athanasiadis; Dhanpat Jain; Jennifer McNiff; Warren D Shlomchik
Journal:  Nat Med       Date:  2004-08-01       Impact factor: 53.440

10.  Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.

Authors:  R C Ash; J T Casper; C R Chitambar; R Hansen; N Bunin; R L Truitt; C Lawton; K Murray; J Hunter; L A Baxter-Lowe
Journal:  N Engl J Med       Date:  1990-02-22       Impact factor: 91.245

View more
  1 in total

Review 1.  Prophylaxis of acute GVHD: manipulate the graft or the environment?

Authors:  A John Barrett; Katarina Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.